HALOZYME THERAPEUTICS, INC. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+22.7% +$41M
$219M
Free Cash Flow↑+24.0% +$42M
$218M
Investing Cash Flow
$202M
Financing Cash Flow
$240M
Capex↓-53.2% -$2M
$1M
Acquisitions
$726M
Stock Buybacks↓-100.0% -$250M
$0
Stock-Based Comp↑+44.6% +$5M
$17M
Debt Issued
—
Debt Repaid
—
D&A↑+24.5% +$651K
$3M
SBC Allocated Expense↑+44.6% +$5M
$17M